Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Subcutaneous injections dominate this segment with a 64% market share, offering robust efficacy and established preference among healthcare providers
AOD 9604/MOTS-c is given as a subcutaneous injection on a provider-determined schedule
5 Counseling Patients on GLP-1s and Pregnancy Prevention Dr Manuel counsels all patients to use an effective form of contraception before starting a GLP-1, as the use of these medications is contraindicated in pregnancy due to limited human safety data and evidence of fetal harm in animal studies. If a patient wishes to become pregnant, she recommends GLP-1 discontinuation 1 to 3 months (depending on the drugs pharmacokinetics) prior to attempting to conceive
Motivation-based wellness program participation and prior authorization are required before drug coverage
